Characterization of Pb51 in Plasmodium berghei as a malaria vaccine candidate targeting both asexual erythrocytic proliferation and transmission

[1]  L. Cui,et al.  Sex-Specific Biology of the Human Malaria Parasite Revealed from the Proteomes of Mature Male and Female Gametocytes * , 2017, Molecular & Cellular Proteomics.

[2]  L. Schlesinger,et al.  Innate Immune Responses to Tuberculosis , 2016, Microbiology spectrum.

[3]  Shabnam Shamriz,et al.  Effect of linker length and residues on the structure and stability of a fusion protein with malaria vaccine application , 2016, Comput. Biol. Medicine.

[4]  C. Long,et al.  Malaria vaccines and human immune responses. , 2016, Current opinion in microbiology.

[5]  T. Bousema,et al.  Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes: molecular insight into sex-specific processes and translational repression , 2016, Nucleic acids research.

[6]  T. Tsuboi,et al.  Identification of three ookinete-specific genes and evaluation of their transmission-blocking potentials in Plasmodium berghei. , 2016, Vaccine.

[7]  L. Cui,et al.  Erratum to: Characterization of a Plasmodium berghei sexual stage antigen PbPH as a new candidate for malaria transmission-blocking vaccine , 2016, Parasites & Vectors.

[8]  H. Ranson,et al.  Insecticide Resistance in African Anopheles Mosquitoes: A Worsening Situation that Needs Urgent Action to Maintain Malaria Control. , 2016, Trends in parasitology.

[9]  E. Takashima,et al.  Vaccine candidates for malaria: what’s new? , 2016, Expert review of vaccines.

[10]  K. Dechering,et al.  Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate—Tackling the Cocktail Challenge , 2015, PloS one.

[11]  C. Proietti,et al.  The case for a rational genome-based vaccine against malaria , 2015, Front. Microbiol..

[12]  Ulrike Böhme,et al.  A comprehensive evaluation of rodent malaria parasite genomes and gene expression , 2014, BMC Biology.

[13]  T. Bousema,et al.  A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. , 2014, Vaccine.

[14]  A. Vaughan,et al.  Malaria vaccine development: persistent challenges. , 2012, Current opinion in immunology.

[15]  J. Sattabongkot,et al.  N-Terminal Prodomain of Pfs230 Synthesized Using a Cell-Free System Is Sufficient To Induce Complement-Dependent Malaria Transmission-Blocking Activity , 2011, Clinical and Vaccine Immunology.

[16]  Ogobara K. Doumbo,et al.  A Research Agenda to Underpin Malaria Eradication , 2011, PLoS medicine.

[17]  Prashant Yadav,et al.  A Research Agenda for Malaria Eradication: Vaccines , 2019 .

[18]  R. Snow,et al.  Shrinking the malaria map: progress and prospects , 2010, Lancet.

[19]  S. Draper,et al.  Blood-stage malaria vaccines — recent progress and future challenges , 2010, Annals of tropical medicine and parasitology.

[20]  Samuel A. Assefa,et al.  New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq , 2010, Molecular microbiology.

[21]  M. P. Cummings,et al.  Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development , 2009, Science Translational Medicine.

[22]  V. A. Stewart,et al.  Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. , 2009, The Journal of infectious diseases.

[23]  M. Demoitié,et al.  Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. , 2008, The New England journal of medicine.

[24]  M. Tanner,et al.  Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. , 2008, The New England journal of medicine.

[25]  M. Fay,et al.  Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51 , 2008, PloS one.

[26]  D. Kelleher,et al.  An evolving view of the eukaryotic oligosaccharyltransferase. , 2006, Glycobiology.

[27]  Oliver Billker,et al.  A NIMA-related Protein Kinase Is Essential for Completion of the Sexual Cycle of Malaria Parasites* , 2005, Journal of Biological Chemistry.

[28]  J. Sattabongkot,et al.  Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. , 2005, Vaccine.

[29]  John R Yates,et al.  A Comprehensive Survey of the Plasmodium Life Cycle by Genomic, Transcriptomic, and Proteomic Analyses , 2005, Science.

[30]  Jonathan E. Allen,et al.  Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.

[31]  T. Richie,et al.  Progress and challenges for malaria vaccines , 2002, Nature.

[32]  R. Sinden,et al.  P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions , 2001, The EMBO journal.

[33]  H. Stunnenberg,et al.  A Central Role for P48/45 in Malaria Parasite Male Gamete Fertility , 2001, Cell.

[34]  K. Mendis,et al.  Malaria transmission-blocking vaccines—how can their development be supported? , 2000, Nature Medicine.

[35]  D. Karaoglu,et al.  Functional characterization of Ost3p. Loss of the 34-kD subunit of the Saccharomyces cerevisiae oligosaccharyltransferase results in biased underglycosylation of acceptor substrates , 1995, The Journal of cell biology.

[36]  R. Carter,et al.  The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. , 1987, Journal of immunology.

[37]  C. Janse,et al.  In vitro formation of ookinetes and functional maturity of Plasmodium berghei gametocytes , 1985, Parasitology.

[38]  T. Burkot,et al.  Target antigens of transmission-blocking immunity on gametes of plasmodium falciparum , 1983, The Journal of experimental medicine.

[39]  R. Fairhurst,et al.  Artemisinin-Resistant Plasmodium falciparum Malaria , 2016, Microbiology spectrum.

[40]  Willy Wriggers,et al.  Control of protein functional dynamics by peptide linkers. , 2005, Biopolymers.